PSquared Asset Management AG Has $1.80 Million Holdings in Abivax SA Sponsored ADR $ABVX

PSquared Asset Management AG raised its position in shares of Abivax SA Sponsored ADR (NASDAQ:ABVX) by 6,650.0% in the first quarter, Holdings Channel reports. The firm owned 16,200 shares of the company’s stock after buying an additional 15,960 shares during the period. Abivax accounts for 0.6% of PSquared Asset Management AG’s investment portfolio, making the stock its 14th largest holding. PSquared Asset Management AG’s holdings in Abivax were worth $1,804,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors also recently made changes to their positions in ABVX. GHP Investment Advisors Inc. lifted its holdings in shares of Abivax by 155.6% during the 1st quarter. GHP Investment Advisors Inc. now owns 230 shares of the company’s stock valued at $26,000 after buying an additional 140 shares during the last quarter. Caitong International Asset Management Co. Ltd increased its holdings in Abivax by 661.5% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 396 shares of the company’s stock worth $53,000 after buying an additional 344 shares during the last quarter. T. Rowe Price Investment Management Inc. bought a new position in Abivax during the fourth quarter valued at approximately $61,000. WPG Advisers LLC raised its position in Abivax by 125.9% during the fourth quarter. WPG Advisers LLC now owns 454 shares of the company’s stock valued at $61,000 after acquiring an additional 253 shares in the last quarter. Finally, Assetmark Inc. acquired a new stake in Abivax in the fourth quarter valued at approximately $84,000. 47.91% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several analysts have commented on the stock. Jefferies Financial Group raised shares of Abivax from a “hold” rating to a “buy” rating and boosted their target price for the stock from $108.00 to $158.00 in a research report on Tuesday, June 30th. Truist Financial lifted their price objective on shares of Abivax from $135.00 to $155.00 and gave the company a “buy” rating in a research note on Thursday, July 2nd. Citizens Jmp reiterated a “market outperform” rating and issued a $187.00 price objective on shares of Abivax in a report on Wednesday, July 1st. Wolfe Research set a $136.00 target price on shares of Abivax in a research report on Wednesday, June 3rd. Finally, Oddo Bhf reaffirmed an “outperform” rating on shares of Abivax in a research report on Thursday, April 9th. Thirteen equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $152.50.

Abivax Price Performance

ABVX stock opened at $131.16 on Friday. The stock has a market capitalization of $11.43 billion, a price-to-earnings ratio of -25.17 and a beta of 0.87. The company has a 50-day moving average of $117.77 and a two-hundred day moving average of $118.20. Abivax SA Sponsored ADR has a 52-week low of $65.67 and a 52-week high of $148.83.

Abivax (NASDAQ:ABVX) last posted its quarterly earnings data on Friday, May 22nd. The company reported ($0.71) EPS for the quarter, topping analysts’ consensus estimates of ($0.94) by $0.23. The business had revenue of $1.56 million during the quarter, compared to the consensus estimate of $0.40 million. Equities analysts expect that Abivax SA Sponsored ADR will post -3.4 EPS for the current fiscal year.

About Abivax

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.